194 related articles for article (PubMed ID: 32222375)
1. Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data.
Rastogi S; Shukla S; Sharma AK; Sarwat M; Srivastava P; Katiyar T; Kalaiselvan V; Singh GN
Toxicol Appl Pharmacol; 2020 May; 395():114976. PubMed ID: 32222375
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the number of report and time-to-onset of the reported adverse event between the biosimilars and the originator of filgrastim.
Kobayashi T; Kamada I; Komura J; Toyoshima S; Ishii-Watabe A
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):917-924. PubMed ID: 28612945
[TBL] [Abstract][Full Text] [Related]
3. Commentary - A comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars and Intended Copy Biologics in treating chemotherapy associated febrile neutropenia.
Cornes PG; Muenzberg M
Toxicol Appl Pharmacol; 2020 Nov; 406():115202. PubMed ID: 32822736
[TBL] [Abstract][Full Text] [Related]
4. Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors.
Abboud CN; Lang N; Fung H; Lammerich A; Buchner A; Liu P; Mueller U; Pettengell R; Diel IJ; Link H; Pathak A
Support Care Cancer; 2019 Jul; 27(7):2569-2577. PubMed ID: 30443809
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
Bassi S; Stroppa EM; Moroni CF; Arbasi MC; Trabacchi E; Di Franco A; Lazzaro A; Bernuzzi P; Moretto M; Arcari A; Bosi C; Riva A; Cavanna L; Vallisa D
Blood Transfus; 2015 Jul; 13(3):478-83. PubMed ID: 25761321
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
Wang CY; Vouri SM; Park H; Heldermon CD; Brown JD
J Manag Care Spec Pharm; 2023 Feb; 29(2):119-127. PubMed ID: 36705287
[No Abstract] [Full Text] [Related]
8. Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.
Pettengell R; Bias P; Mueller U; Lang N
Support Care Cancer; 2016 Jun; 24(6):2677-84. PubMed ID: 26780505
[TBL] [Abstract][Full Text] [Related]
9. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
10. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients.
Botteri E; Krendyukov A; Curigliano G
Eur J Cancer; 2018 Jan; 89():49-55. PubMed ID: 29227817
[TBL] [Abstract][Full Text] [Related]
11. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study.
Nahon S; Rastkhah M; Ben Abdelghani M; Soumoudronga RF; Gasnereau I; Labourey JL
Support Care Cancer; 2016 May; 24(5):1991-1998. PubMed ID: 26507190
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with Zarzio® in Europe: what have we learned?
Gascón P; Tesch H; Verpoort K; Rosati MS; Salesi N; Agrawal S; Wilking N; Barker H; Muenzberg M; Turner M
Support Care Cancer; 2013 Oct; 21(10):2925-32. PubMed ID: 23903799
[TBL] [Abstract][Full Text] [Related]
13. Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation study.
Yousef CC; Khan MA; Almodaimegh H; Alshamrani M; Al-Foheidi M; AlAbdalkarim H; AlJedai A; Naeem A; Abraham I
J Med Econ; 2023; 26(1):394-402. PubMed ID: 36815700
[TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy.
Schwartzberg LS; Lal LS; Balu S; Campbell K; Brekke L; DeLeon A; Elliott C; Korrer S
J Manag Care Spec Pharm; 2018 Oct; 24(10):976-984. PubMed ID: 29687743
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of Brand and Biosimilar Granulocyte-Colony Stimulating Factors for Prophylaxis of Chemotherapy-Induced Febrile Neutropenia.
Douglas AG; Schwab P; Lane D; Kennedy K; Slabaugh SL; Bowe A
J Manag Care Spec Pharm; 2017 Dec; 23(12):1221-1226. PubMed ID: 29172983
[TBL] [Abstract][Full Text] [Related]
16. The comparison of effectiveness and safety between different biosimilars of G-CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral blood stem cell transplantation, auto-PBSCT).
Wicherska-Pawłowska K; Rybka J; Prajs I; Szmigiel K; Tyc J; Frączak E; Biedroń M; Kalicińska E; Szymczak D; Wróbel T
J Clin Apher; 2020 Jan; 35(1):4-8. PubMed ID: 31663634
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
Roché H; Eymard JC; Radji A; Prevost A; Diab R; Lamuraglia M; Soumoudronga RF; Gasnereau I; Toledano A
BMC Cancer; 2018 Nov; 18(1):1127. PubMed ID: 30445935
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
Harbeck N; Gascón P; Krendyukov A; Hoebel N; Gattu S; Blackwell K
Oncologist; 2018 Apr; 23(4):403-409. PubMed ID: 29317553
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study).
Gascón P; Aapro M; Ludwig H; Bokemeyer C; Boccadoro M; Turner M; Denhaerynck K; MacDonald K; Abraham I
Support Care Cancer; 2016 Feb; 24(2):911-925. PubMed ID: 26306517
[TBL] [Abstract][Full Text] [Related]
20. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR).
Bongiovanni A; Monti M; Foca F; Recine F; Riva N; Di Iorio V; Liverani C; De Vita A; Miserocchi G; Mercatali L; Amadori D; Ibrahim T
Support Care Cancer; 2017 Jan; 25(1):111-117. PubMed ID: 27568305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
